+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06892951

Safety and Efficacy Study of Nebulized Caspofungin with Standard Antifungal Treatment for Pneumocystis Pneumonia A Phase III Randomized, Placebo-Controlled Trial

Led by University Hospital, Tours · Updated on 2026-10-09

100

Participants Needed

3

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness of daily caspofungin aerosols compared to placebo, alongside standard systemic antifungal therapy, for treating Pneumocystis pneumonia. This trial aims to support a decision about moving forward to a larger phase III trial. Pneumocystis jirovecii causes severe pneumonia especially in immunocompromised patients, with high rates of hospitalization, mechanical ventilation, and mortality. Current treatments have limitations and side effects, so new delivery methods like aerosolized caspofungin are being explored. The study includes two parts an initial open-label dose escalation phase to determine the best nebulized caspofungin regimen, followed by a randomized, blinded, placebo-controlled phase comparing daily caspofungin aerosol or placebo aerosols alongside conventional systemic antifungal treatments. Caspofungin aerosols are delivered via a vibrating mesh nebulizer once daily for up to seven days. Placebo aerosols contain saline and are administered similarly. The trial uses conventional systemic antifungal drugs such as co-trimoxazole or second-line salvage therapies in all groups. Participants will be closely monitored during treatment for safety and effectiveness, with assessments including clinical outcomes at day 7, fungal clearance, lung infection markers, pharmacokinetics of nebulized caspofungin, mortality up to day 90, and morbidity. Safety is assessed daily during inhalation therapy. The trial duration includes up to seven days of aerosol treatment with follow-up visits extending to day 90 to evaluate longer-term outcomes and adverse events.

CONDITIONS

Brief Title

CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia

Research Team

G

Guillaume DESOUBEAUX, Prof

S

Stephan EHRMANN, Prof

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here